Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 14/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.41 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.41 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.41 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.41 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.41 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17310957 | 0.84 | P2RX7 (0.59) | P2RX7PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL3837306 | 0.81 | LMNA (0.53) | P2RX7 | |
| SCHEMBL4918236 | 0.76 | P2RX7 (0.36) | P2RX7PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4929353 | 0.76 | P2RX7 (0.36) | P2RX7PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4779101 | 0.76 | NPC1 (0.51) | SMPD3 | |
| SCHEMBL5128181 | 0.75 | MAP4K4 (0.43) | P2RX7 | |
| SCHEMBL12701400 | 0.74 | P2RX7 (0.45) | P2RX7PDE10A | |
| SCHEMBL5122944 | 0.74 | SHMT2 (0.62) | — | |
| SCHEMBL5744327 | 0.73 | P2RX7 (0.68) | P2RX7 | |
| SCHEMBL1804218 | 0.73 | P2RX7 (0.68) | P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058309-A1 | Novel Compounds 171 | ASTRAZENECA AB | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058309-A1 | Novel Compounds 171 | C1R, F12, ADRA1D | P2RX7 309/4885PDE10A 184/4885PRKAB2 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.